Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study.
Hizal M, Bilgin B, Paksoy N, Kılıçkap S, Atcı MM, Kahraman S, Keskinkılıç M, Bilgetekin İ, Ayhan M, Tural D, Eren Ö, Akkoç Mustafayev FN, Yaman Ş, Tatlı AM, Bayram E, Kutlu Y, Ertürk İ, Özcan E, Gülmez A, Korkmaz M, Akagündüz B, Erdem D, Telli TA, Aksoy A, Üskent N, İriağaç Y, Baytemür NK, Aydın D, Şakalar T, Arak H, Selçukbiricik F, Ergün Y, Korkmaz T, Ak N, Ünal Ç, Akdeniz N, Özgün MA, Öksüzoğlu B, Yalçın B, Öztop İ, Algın E, Sakin A, Aydıner A, Yumuk PF, Şendur MAN. Hizal M, et al. Among authors: oztop i. Future Oncol. 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083. Epub 2022 Jun 23. Future Oncol. 2022. PMID: 35734870
Predictive factors for the development of brain metastases in patients with malignant melanoma: a study by the Anatolian society of medical oncology.
Gumusay O, Coskun U, Akman T, Ekinci AS, Kocar M, Erceleb OB, Yazıcı O, Kaplan MA, Berk V, Cetin B, Taskoylu BY, Yildiz A, Goksel G, Alacacioglu A, Demirci U, Algin E, Uysal M, Oztop I, Oksuzoglu B, Dane F, Gumus M, Buyukberber S. Gumusay O, et al. Among authors: oztop i. J Cancer Res Clin Oncol. 2014 Jan;140(1):151-7. doi: 10.1007/s00432-013-1553-7. Epub 2013 Nov 29. J Cancer Res Clin Oncol. 2014. PMID: 24292400
Treatment and prognostic factors in primary peritoneal carcinoma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO).
Unal OU, Oztop I, Yazici O, Ozatli T, Inal A, Günaydın Y, Alici S, Demirci U, Cinkir HY, Aktas B, Aslan K, Uncu D, Yilmaz AU, Oksuzoglu B, Buyukberber S. Unal OU, et al. Among authors: oztop i. Oncol Res Treat. 2014;37(6):332-8. doi: 10.1159/000362857. Epub 2014 May 19. Oncol Res Treat. 2014. PMID: 24903764 Clinical Trial.
Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma.
Turan N, Benekli M, Unal OU, Unek İT, Tastekin D, Dane F, Algın E, Ulger S, Eren T, Topcu TO, Turkmen E, Babacan NA, Tufan G, Urakci Z, Ustaalioglu BO, Uysal OS, Ercelep OB, Taskoylu BY, Aksoy A, Canhoroz M, Demirci U, Dogan E, Berk V, Balakan O, Ekinci AŞ, Uysal M, Petekkaya İ, Ozturk SC, Tonyalı Ö, Çetin B, Aldemir MN, Helvacı K, Ozdemir N, Oztop İ, Coskun U, Uner A, Ozet A, Buyukberber S; Anatolian Society of Medical Oncology (ASMO). Turan N, et al. Among authors: oztop i. Chin J Cancer Res. 2015 Aug;27(4):408-16. doi: 10.3978/j.issn.1000-9604.2015.08.03. Chin J Cancer Res. 2015. PMID: 26361410 Free PMC article.
Evaluation of Prognostic Factors and Adjuvant Chemotherapy in Patients With Small Bowel Adenocarcinoma Who Underwent Curative Resection.
Aydin D, Sendur MA, Kefeli U, Unal OU, Tastekin D, Akyol M, Tanrikulu E, Ciltas A, Ustaalioglu BB, Uysal M, Esbag O, Yazilitas D, Tanrıverdi O, Bilici A, Arpaci E, Berk V, Yetisyigit T, Ozdemir NY, Oztop I, Alacacioglu A, Aydin O, Ozcelik M, Yildirim E, Dinc N, Gumus M. Aydin D, et al. Among authors: oztop i. Clin Colorectal Cancer. 2017 Sep;16(3):220-227. doi: 10.1016/j.clcc.2016.08.002. Epub 2016 Aug 30. Clin Colorectal Cancer. 2017. PMID: 27670893
GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients.
Peled N, Gillis R, Kilickap S, Froesch P, Orlov S, Filippova E, Demirci U, Christopoulos P, Cicin I, Basal FB, Yilmaz C, Fedor M, Korkmaz T, Paydas S, Gautschi O, Zirtiloglu A, Eralp Y, Cinkir HY, Sezer A, Erman M, Tural D, Turna H, Mazieres J, Dudnik E, Reguart N, Camidge DR, Ng TL, Şenler FÇ, Beypınar İ, Yazılıtaş D, Demirkazık A, Karaoğlu A, Okutur K, Coşkun HŞ, Şendur MAN, Isikdogan A, Cabuk D, Yumuk PF, Yıldız I, Kaplan MA, Özyılkan Ö, Öztop İ, Olmez OF, Aydin K, Aydıner A, Meydan N, Grinberg RD, Roisman LC. Peled N, et al. Among authors: oztop i. Lung Cancer. 2020 Oct;148:48-54. doi: 10.1016/j.lungcan.2020.07.022. Epub 2020 Jul 27. Lung Cancer. 2020. PMID: 32799090
The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study).
Hizal M, Bilgin B, Paksoy N, Atcı MM, Kahraman S, Kılıçkap S, Güven DC, Keskinkılıç M, Ayhan M, Eren Ö, Mustafayev FNA, Yaman Ş, Bayram E, Ertürk İ, Özcan E, Korkmaz M, Akagündüz B, Erdem D, Telli TA, Aksoy A, Üskent N, Baytemür NK, Gülmez A, Aydın D, Şakalar T, Arak H, Tatlı AM, Ergün Y, Ak N, Ünal Ç, Özgün MA, Yalçın B, Öztop İ, Algın E, Sakin A, Aydıner A, Yumuk PF, Şendur MAN. Hizal M, et al. Among authors: oztop i. J Cancer Res Clin Oncol. 2023 Jul;149(8):4141-4148. doi: 10.1007/s00432-022-04252-2. Epub 2022 Sep 1. J Cancer Res Clin Oncol. 2023. PMID: 36048274
121 results